Galera Therapeutics, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
OQB
Galera Therapeutics reports a significant net income of $149 million for 2025, driven by asset sales and a strategic pivot to advanced breast cancer therapies after divesting its dismutase mimetics portfolio.
OQB
Galera Therapeutics pivots to breast cancer drug development following the acquisition of Nova Pharmaceuticals, focusing on aggressive subtypes like metaplastic breast cancer.
OQB
Galera Therapeutics halts clinical trials and explores strategic alternatives following an FDA rejection and disappointing trial results.